As Cerulean continues to grow and advance our technologies and programs, we are committed to clear and consistent communication to our external audiences. Here we feature current and historic information concerning our technology, our pipeline and our corporate goals and achievements. Please check in often for the most recent press releases and news coverage.

07.28.09:: Cerulean Pharma Inc. Closes $10 Million Series B-1 Financing - Company Appoints Acting Chief Medical Officer, John Ryan, to advance clinical trial with lead nanopharmaceutical product candidate. View Press Release

06.23.09:: Cerulean Pharma Inc. Announces License Agreement with Calando Pharmaceuticals, Inc., a Subsidiary of Arrowhead Research Corporation View Press Release

04.08.09:: Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and Chief Executive Officer View Press Release

01.23.09:: Sandra Glucksmann Named 2009 Mass High Tech Woman to Watch View Press Release

10.24.08 :: Tempo Pharmaceuticals, Inc. Announces Name Change to Cerulean Pharma Inc. View Press Release

01.03.08 :: Tempo Pharmaceuticals Closes $8 Million in Series B Funding View Press Release

05.23.07 :: Tempo Pharmaceuticals Closes $12.1 Million in Series A Funding View Press Release